A recent retrospective review that investigated adverse events caused by the group of five FDA-approved PD-1/PD-L1 inhibitors, reported 72 cases of active TB and 13 cases of atypical mycobacterial infections out of a total of 73,886 adverse events (3). Here, PDCD1 is linked to tuberculosis.